Reason for request
Assessment of change of dose permitting use in children aged between 2 and 16.
Clinical Benefit
| Substantial |
The clinical benefit provided by DUROGESIC in children is substantial. |
Clinical Added Value
| Comments without ASMR value |
DUROGESIC has previously been recognised by the Transparency Committee as providing actual benefit in adults, and it provides the same benefit for children over 2. |
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
xSY4FDHjmHpF3R6Z
